Microorganism producing purine nucleotides, and method for producing purine nucleotides using same
Patent Information
- Application Number
- MYPI2025002661
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-01
- Filing Date
- 2023-11-01
- Publication Date
- 2024-05-01
AI Technical Summary
Purine nucleotide production in microorganisms decreases due to oxidative stress during long-term aerobic fermentation, leading to reduced productivity.
Introduction of an Mn transporter with enhanced activity into microorganisms of the genus Corynebacterium to increase purine nucleotide production, specifically by culturing these microorganisms in a medium with optimized conditions to enhance Mn transporter activity.
The enhanced Mn transporter activity in Corynebacterium microorganisms significantly increases purine nucleotide production compared to unmodified strains, improving fermentation efficiency and productivity.
Abstract
Description
Microorganism producing purine nucleotides and method for producing purine nucleotides using the same
[0001] The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using the same.
[0002]
[0003] Purine nucleotides are intermediate substances in the nucleic acid biosynthesis metabolic system, play physiologically important roles in the body, and are widely used in foods, medicines, etc. The purine nucleotides include 5'-inosine monophosphate (IMP), 5'-xanthosine monophosphate (XMP), and 5'-guanosine monophosphate (GMP).
[0004] To produce purine nucleotides such as the above IMP, XMP, and GMP, various studies are being conducted to develop high-efficiency production microorganisms and fermentation process technologies. For example, target substance-specific approaches such as increasing the expression of genes encoding enzymes involved in the biosynthesis of IMP, XMP, and GMP or removing genes unnecessary for biosynthesis are mainly utilized (EP 3722430 A1, US 2020-0347346 A1).
[0005] However, when the purine nucleotide is produced through aerobic fermentation from a microorganism that produces it, there was a problem that productivity decreased due to oxidative stress in the latter half of the fermentation when the culture continued for a long time.
[0006]
[0007] The present inventors completed the present application by confirming that purine nucleotide production ability is increased compared to existing unmodified microorganisms by introducing a Mn transporter with enhanced activity into the microorganism.
[0008]
[0009] One object of the present application is to provide a microorganism of the genus Corynebacterium that produces purine nucleotides and has enhanced activity of a Mn transporter.
[0010] Another object of the present application is to provide a method for producing purine nucleotides, which comprises the step of culturing a Corynebacterium genus microorganism having enhanced activity of a Mn transporter and producing purine nucleotides in a medium.
[0011] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a Corynebacterium microorganism having enhanced activity of a Mn transporter; a medium in which the same is cultured; or a combination thereof.
[0012]
[0013] The microorganism of the present application can increase its purine nucleotide production ability compared to existing unmodified microorganisms as the activity of the Mn transporter is enhanced.
[0014]
[0015] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below. Furthermore, numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification in their entirety by reference to more clearly explain the level of the technical field to which this application belongs and the contents of this application.
[0016]
[0017] One aspect of the present application provides a microorganism of the genus Corynebacterium that produces purine nucleotides and has enhanced activity of a Mn transporter.
[0018]
[0019] In this application, the term "Mn transporter" refers to a protein that transports manganese (Mn), and belongs to the Iron / manganese / zinc ABC (TroA-like ATP-binding cassette) transporter.
[0020] The amino acid sequence of the above Mn transporter can be obtained from a known database such as NCBI's Genebank.
[0021] For example, the Mn transporter of the present application may be derived from a microorganism. The microorganism may be specifically derived from a microorganism of the genus Corynebacterium, and more specifically, may be derived from, but is not limited to, Corynebacterium stationis, Corynebacterium sp. J010B-136, Corynebacterium casei, Corynebacterium ammoniagenes, etc.
[0022] As another example, the amino acid sequence of the Mn transporter of the present application may be WP_066796334.1 derived from Corynebacterium stationenis ATCC6872, but it is obvious that it includes proteins having Mn transporter activity of various origins.
[0023]
[0024] In the present application, the Mn transporter may have, include, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 1.
[0025] In the present application, the amino acid sequence of SEQ ID NO: 1 may include an amino acid sequence having at least 70%, 75%, 76%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity with the amino acid sequence of SEQ ID NO: 1. In addition, it is obvious that a protein having an amino acid sequence in which a part of the sequence is deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present application, as long as it is an amino acid sequence that has such homology or identity and exhibits an effect corresponding to a protein including the amino acid sequence of SEQ ID NO: 1.
[0026] For example, if the amino acid sequence has sequence additions or deletions, naturally occurring mutations, silent mutations or conservative substitutions that do not alter the function of the protein of the present application at the N-terminus, C-terminus and / or within the amino acid sequence.
[0027] The term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions may have little or no effect on the activity of a protein or polypeptide.
[0028]
[0029] In this application, the terms "homology" or "identity" refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms "homology" and "identity" are often used interchangeably.
[0030] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.
[0031] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example, as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ET AL / .](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database.
[0032] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and (2) a comparison matrix as disclosed by Gribskov et al. (1986) Nucl. Acids Res. 48:443, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979). 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) permutation matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.
[0033]
[0034] The Mn transporter of the present application may be encoded by the znuA1 gene.
[0035] As an example, the znuA1 gene may be a polynucleotide encoding WP_066796334.1 derived from Corynebacterium stationensis ATCC6872, but is not limited thereto. As another example, the znuA1 gene may be a part of Ncam2275 or CP016326.1 derived from Corynebacterium stationensis ATCC6872, but is not limited thereto, and it is apparent that various derived znuA1 genes encoding proteins having Mn transporter activity are included.
[0036] In this application, the term "polynucleotide" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, a DNA or RNA strand of a certain length or longer, and more specifically, a polynucleotide fragment that encodes the protein.
[0037] The polynucleotide encoding the Mn transporter of the present application may include a base sequence encoding the amino acid sequence of SEQ ID NO: 1. As an example of the present application, the polynucleotide of the present application may have or include the base sequence of SEQ ID NO: 2. In addition, the polynucleotide of the present application may consist of, or consist essentially of, the base sequence of SEQ ID NO: 2. Specifically, the znuA1 gene may be encoded by a polynucleotide described by the base sequence of SEQ ID NO: 2.
[0038] The polynucleotide of the present application may have various modifications made to the coding region within a range that does not change the amino acid sequence of the Mn transporter, taking into account the degeneracy of the codon or the codon preferred in the organism that is to express the Mn transporter of the present application. Specifically, the polynucleotide of the present application has or includes a base sequence having at least 70%, at least 75%, at least 76%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology or identity with the sequence of SEQ ID NO: 2, or may consist of or essentially consist of a base sequence having at least 70%, at least 75%, at least 76%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology or identity with the sequence of SEQ ID NO: 2, but is not limited thereto.
[0039] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application. The term "stringent conditions" refers to conditions that enable specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 70% or more, 75% or more, 76% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, are performed.
[0040] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.
[0041] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.
[0042] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0043]
[0044] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification naturally or artificially, and may be a microorganism that has a specific mechanism strengthened or weakened due to causes such as the insertion of an external gene or the strengthening or weakening of the activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein or product.
[0045] Therefore, as an example of the microorganism of the present application, a recombinant microorganism having a genetic modification that enhances Mn transporter activity can be mentioned.
[0046] The microorganism of the present invention may have increased Mn transporter activity compared to its intrinsic activity.
[0047] For example, the microorganism of the present application may have increased expression of the Mn transporter and enhanced activity of the Mn transporter compared to a wild-type Corynebacterium microorganism, but is not limited thereto.
[0048]
[0049] In this application, the term "enhancement" of a polypeptide (including, for example, a protein specified by the name of each enzyme) means that the activity of the polypeptide is increased compared to the intrinsic activity. The enhancement may be used interchangeably with terms such as activation, up-regulation, overexpression, and increase. Here, activation, enhancement, up-regulation, overexpression, and increase may all include exhibiting an activity that was not originally present, or exhibiting an activity that was enhanced compared to the intrinsic activity or the activity before modification. The "intrinsic activity" refers to the activity of a specific polypeptide that a parent strain or an unmodified microorganism originally had before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "pre-modification activity." "Enhanced," "upregulated," "overexpressed," or "increased" the activity of a polypeptide relative to its intrinsic activity means that the activity and / or concentration (expression amount) of the specific polypeptide is improved compared to the activity and / or concentration (expression amount) that the parent strain or unmodified microorganism originally had prior to the transformation.
[0050] The above enhancement can be achieved by introducing an exogenous polypeptide, or by enhancing the activity and / or concentration (expression level) of an endogenous polypeptide. Whether the activity of the polypeptide is enhanced can be determined by an increase in the level of activity, expression level, or amount of product excreted from the polypeptide.
[0051] For the purpose of the present application, the microorganism of the present application has an enhanced purine nucleotide production ability due to the activity of an enhanced Mn transporter, and the target strains for comparing the increase in the purine nucleotide production ability or the Mn transporter, the non-modified microorganisms without an enhanced Mn transporter, are Corynebacterium stationensis KCCM12151P (CJI0323, Republic of Korea Registration No. 10-1904675), a 5'-inosine monophosphate (IMP) producing strain, Corynebacterium stationensis KCCM12285P (CJX1664, Republic of Korea Patent No. 10-1950141), and Corynebacterium stationensis It may be KCCM12313P (CJX1682, Republic of Korea Patent No. 10-2006977), but is not limited thereto.
[0052] Enhancement of the activity of the above polypeptide can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be enhanced compared to that of the microorganism before modification. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but is not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
[0053] Specifically, the enhancement of the activity of the polypeptide of the present application is
[0054] 1) Increase in the intracellular copy number of a polynucleotide encoding a polypeptide;
[0055] 2) Replacing the gene expression control region on the chromosome encoding the polypeptide with a highly active sequence;
[0056] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;
[0057] 4) Modification of the amino acid sequence of the polypeptide so as to enhance polypeptide activity;
[0058] 5) Modification of the polynucleotide sequence encoding the polypeptide so as to enhance the activity of the polypeptide (e.g., modification of the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so as to enhance the activity of the polypeptide);
[0059] 6) Introduction of a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same;
[0060] 7) Codon optimization of a polynucleotide encoding a polypeptide;
[0061] 8) Analyzing the tertiary structure of the polypeptide and selecting the exposed portion to modify or chemically modify; or
[0062] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0063] More specifically,
[0064] The increase in the intracellular copy number of the polynucleotide encoding the polypeptide described above may be achieved by introducing into the host cell a vector capable of replicating and functioning independently of the host, to which the polynucleotide encoding the polypeptide is operably linked. Alternatively, the polynucleotide encoding the polypeptide may be achieved by introducing one copy or two or more copies into the chromosome of the host cell. The introduction into the chromosome may be performed by introducing into the host cell a vector capable of inserting the polynucleotide into the chromosome of the host cell, but is not limited thereto. The vector is as described above.
[0065] 2) Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence having strong activity may be, for example, a mutation in the sequence such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control region, or replacement with a sequence having stronger activity. The expression control region may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. As an example, it may be, but is not limited to, replacing the original promoter with a strong promoter.
[0066] Examples of known strong promoters include, but are not limited to, the CJ1 to CJ7 promoters (Republic of Korea Registration No. 10-0620092, U.S. Patent No. US 7662943 B2), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (U.S. Patent No. US 10584338 B2), the O2 promoter (U.S. Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.
[0067] The above 3) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a higher polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0068] The modification of the amino acid sequence or polynucleotide sequence of the above 4) and 5) may be, but is not limited to, a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution or a combination thereof in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to enhance the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to have increased activity. The replacement may be specifically performed by inserting the polynucleotide into a chromosome by homologous recombination, but is not limited thereto. The vector used at this time may additionally include a selection marker to confirm whether or not chromosomal insertion has occurred.
[0069] The introduction of the foreign polynucleotide exhibiting the activity of the polypeptide as described above 6) may be the introduction into the host cell of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide. The foreign polynucleotide is not limited in its origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction may be performed by a person skilled in the art by appropriately selecting a known transformation method, and the polypeptide may be produced by expressing the introduced polynucleotide in the host cell, thereby increasing its activity.
[0070] The above 7) codon optimization of a polynucleotide encoding a polypeptide may be codon optimization of an endogenous polynucleotide to increase transcription or translation within a host cell, or codon optimization of a foreign polynucleotide to achieve optimized transcription or translation within a host cell.
[0071] The above 8) analyzing the tertiary structure of a polypeptide and selecting an exposed portion to modify or chemically modify may be done by, for example, comparing the sequence information of the polypeptide to be analyzed with a database storing the sequence information of known proteins, determining a template protein candidate based on the degree of sequence similarity, confirming the structure based on this, and selecting an exposed portion to modify or chemically modify, and modifying or modifying it.
[0072] Such enhancement of polypeptide activity may be, but is not limited to, an increase in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or an increase in the amount of a product produced from the polypeptide.
[0073] For example, the enhancement of the activity of the Mn transporter of the present application may be due to an increase in the intracellular copy number of a polynucleotide encoding the Mn transporter. As another example, the enhancement of the activity of the Mn transporter of the present application may be due to replacement of the promoter of the gene encoding the Mn transporter or due to modification of the promoter. As another example, the enhancement of the activity of the Mn transporter of the present application may be due to the introduction of a polynucleotide exhibiting the activity of the Mn transporter. However, the present invention is not limited thereto.
[0074]
[0075] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.
[0076]
[0077] The vector of the present application may comprise a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may comprise a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. The vector may be capable of replicating or functioning independently of the host genome after being transformed into a suitable host cell, or may be integrated into the genome itself.
[0078] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors can be used.
[0079] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0080] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or outside the chromosome, as long as it can be expressed in the host cell. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The above expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0081] Additionally, the term "operably linked" as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target polypeptide of the present application.
[0082]
[0083] As another example of the present application, the microorganism of the present application may be a microorganism having the ability to produce purine nucleotides.
[0084] The microorganism of the present application may be a microorganism with improved purine nucleotide production ability.
[0085]
[0086] In this application, "purine nucleotide" means a nucleotide containing a purine structure. The purine nucleotide may be XMP, IMP, GMP or AMP, and may be specifically IMP, XMP or GMP, but is not limited thereto.
[0087] The "IMP (inosine 5'-monophosphate, 5'-inosinic acid)" and "GMP (guanosine-5'-monophosphate, 5'-Guanylic acid)" of the present application are intermediate substances in the nucleic acid biosynthesis metabolic system, which play an important physiological role in the body and are widely used in foods, medicines, etc. Specifically, IMP is known to have a beefy flavor on its own, and GMP derived from XMP is known to have a mushroom flavor. Both substances are known to enhance the flavor of monosodium glutamate (MSG), and are thus attracting attention as a savory nucleic acid seasoning.
[0088] In one implementation example, GMP can be manufactured by conversion from XMP, but is not limited thereto. For example, GMP can also be converted from XMP with increased production volume to increase production volume, and it is obvious that the GMP is also included in the scope of the present application.
[0089] The “XMP” of the present application is also called xanthosine-5'-monophosphate, 5'-Xanthylic acid, and can be formed from IMP through the action of IMP dehydrogenase or converted into GMP through the action of GMP synthase.
[0090]
[0091] The microorganism of the present application may have enhanced Mn transporter activity. Specifically, the microorganism of the present application may be a microorganism having an enhanced Mn transporter or the znuA1 gene encoding it; or a microorganism genetically modified to have an enhanced Mn transporter or the znuA1 gene encoding it (e.g., a recombinant microorganism), but is not limited thereto.
[0092] The microorganism of the present application may be a microorganism that naturally has purine nucleotide production ability or a parent strain that does not have purine nucleotide production ability, but may be a microorganism that has increased or been granted purine nucleotide production ability by enhancing a Mn transporter or a polynucleotide encoding the same, but is not limited thereto.
[0093] For the purpose of the present application, the recombinant microorganism of the present application may be a microorganism having increased purine nucleotide production ability compared to a naturally occurring wild-type microorganism or a microorganism producing purine nucleotides, including a Mn transporter or a polynucleotide encoding the same, by enhancing the Mn transporter or the polynucleotide encoding the same in the microorganism, but is not limited thereto. For example, the naturally occurring wild-type microorganism or the microorganism producing purine nucleotides, including a Mn transporter or a polynucleotide encoding the same, may be a target strain for comparing whether the purine nucleotide production ability or the Mn transporter is increased as described above, but is not limited thereto.
[0094] For example, the recombinant strain with increased productivity has a purine nucleotide productivity of about 1% or more, specifically, about 2% or more, about 5% or more, about 5.4% or more, about 5.7% or more, about 6% or more, about 6.7% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more, about 11.5% or more, about 12% or more, about 12.9% or more, about 13% or more, about 14% or more, about 14.4% or more, about 15% or more, about 16% or more, about 17% or more, about 18% or more, about 19% or more, or about 20% or more (the upper limit is not particularly limited, and for example, about 200% or less, about 150% or less, about 100% or less, about It may be increased by 50% or less, about 40% or less, about 30% or less, about 20% or less, or about 15% or less), but is not limited thereto, as long as it has a positive increase compared to the productivity of the parent strain or unmodified microorganism before the mutation. In another example, the microorganism with increased productivity has a purine nucleotide productivity of about 1.01 times or more, about 1.02 times or more, about 1.05 times or more, about 1.054 times or more, about 1.057 times or more, about 1.06 times or more, about 1.067 times or more, about 1.07 times or more, about 1.08 times or more, about 1.09 times or more, about 1.10 times or more, about 1.11 times or more, about 1.115 times or more, about 1.12 times or more, about 1.129 times or more, about 1.13 times or more, about 1.14 times or more, about 1.144 times or more, about 1.15 times or more, about 1.16 times or more, about 1.17 times or more, about 1.18 times or more, about It may be increased by 1.19 times or more or about 1.20 times or more (the upper limit is not particularly limited, for example, it may be about 10 times or less, about 5 times or less, about 3 times or less, or about 2 times or less), but is not limited thereto.
[0095] This productivity can be evaluated by measuring the production amount of the target product obtained by culturing in a medium. The evaluation can be performed by measuring the production amount of the target product using a suitable method known in the art. For example, HPLC (High Performance Liquid Chromatography), GC (Gas Chromatography), GC / MS (Gas Chromatography-Mass Spectrometry), LC / MS (Liquid chromatography-mass spectrometry), GPC (Gel Permeation Chromatography), or a combination of these methods can be used, and the production amount of the target product can be measured using a suitable method known in the art.
[0096] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation caused by natural or artificial factors. For example, the unmodified microorganism may refer to a strain in which the Mn transporter described herein or the polynucleotide encoding it is not enhanced or before it is enhanced. The "unmodified microorganism" may be used interchangeably with "pre-modified strain," "pre-modified microorganism," "unmutated strain," "unmodified microorganism," "unmutated microorganism," or "reference microorganism."
[0097] In the present application, the purine nucleotide may be at least one selected from the group consisting of IMP, XMP, and GMP. This is as described above.
[0098]
[0099] In another example of the present application, the microorganism of the present application is Corynebacterium stationis, Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens, and specifically, but not limited to, Corynebacterium stationis.
[0100]
[0101] As another example of the present application, the recombinant microorganism of the present application may be a microorganism with enhanced purine nucleotide production ability, whereby the activity of a portion of a protein in the purine nucleotide biosynthesis pathway is further enhanced, or the activity of a portion of a protein in the purine nucleotide degradation pathway is further weakened.
[0102]
[0103] In this application, the term "attenuation" of the activity of a polypeptide encompasses both a decrease in activity or the absence of activity compared to the intrinsic activity. The term "attenuation" may be used interchangeably with terms such as inactivation, deficiency, down-regulation, decrease, reduce, and attenuation.
[0104] The above weakening may also include cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall polypeptide activity level and / or concentration (expression amount) within the cell is lower than that of the natural strain due to inhibition of expression of the gene of the polynucleotide encoding the polypeptide or inhibition of translation into a polypeptide, cases where the polynucleotide is not expressed at all, and / or cases where the polypeptide has no activity even if the polynucleotide is expressed. The above "intrinsic activity" refers to the activity of a specific polypeptide originally possessed by the parent strain, wild type, or unmodified microorganism before the change in trait when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before modification." The term "weakening, inactivation, deficiency, reduction, downregulation, deterioration, attenuation" of the activity of a polypeptide relative to its intrinsic activity means that the activity of a particular polypeptide is lowered compared to the activity that the parent strain or unmodified microorganism originally had prior to the transformation.
[0105] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).
[0106]
[0107] Specifically, the weakening of the activity of the polypeptide of the present application is
[0108] 1) Deletion of all or part of a gene encoding a polypeptide;
[0109] 2) Modification of the expression control region (or expression control sequence) so as to reduce the expression of the gene encoding the polypeptide;
[0110] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;
[0111] 4) Modification of the gene sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotide bases in the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);
[0112] 5) Modification of the base sequence encoding the initiation codon, Shine-Dalgarno sequence or 5'-UTR region of a gene transcript encoding a polypeptide;
[0113] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;
[0114] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence to the front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible;
[0115] 8) Addition of a promoter that is transcribed in the opposite direction to the 3' end of the open reading frame (ORF) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE); or
[0116] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.
[0117] for example,
[0118] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having some nucleotides deleted, or replacement with a marker gene.
[0119] The above 2) modification of the expression control region (or expression control sequence) may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0120] The modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of the gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.
[0121] The above 5) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.
[0122] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].
[0123] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible may render mRNA translation impossible or slow it down.
[0124] In addition, the addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.
[0125]
[0126] Another aspect of the present application provides a method for producing purine nucleotides, comprising the step of culturing a Corynebacterium genus microorganism having enhanced activity of a Mn transporter and producing purine nucleotides in a medium.
[0127] The method for producing purine nucleotides of the present application may include a step of culturing a microorganism in which a Mn transporter or a znuA1 gene encoding the same is enhanced, or a microorganism genetically modified to enhance a Mn transporter or a znuA1 gene encoding the same, in a medium, wherein the microorganism is as described above.
[0128]
[0129] In this application, the term "cultivation" refers to growing the microorganism of this application under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected microorganism. Specifically, the culturing process may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0130] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the microorganism of this application may be any medium used for culturing general microorganisms without particular limitation, but the microorganism of this application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin.
[0131] Specifically, culture media for microorganisms of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0132] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0133] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0134] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0135] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or in order to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0136] In the culture of the present application, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.
[0137] Purine nucleotides produced by the culture of the present invention may be secreted into the medium or remain within the cells.
[0138] The above purine nucleotide may be at least one selected from the group consisting of IMP, XMP and GMP.
[0139]
[0140] The method for producing purine nucleotides of the present application may additionally include a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the microorganism, or a combination thereof (in any order), for example, before the culturing step.
[0141] The purine nucleotide production method of the present application may further include a step of recovering purine nucleotides from the culture medium (medium in which culture is performed) or the cultured microorganism. The recovering step may be additionally included after the culturing step.
[0142] The above recovery may be performed by collecting the desired purine nucleotide using a suitable method known in the art according to the culture method of the microorganism of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the desired purine nucleotide may be recovered from the medium or microorganism using a suitable method known in the art.
[0143] Additionally, the purine nucleotide production method of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the purine nucleotide production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0144] In the method of the present application, the Mn transporter, polynucleotide, vector, microorganism, etc. are as described in the other aspects above.
[0145]
[0146] Another aspect of the present application provides a composition for producing purine nucleotides, comprising a Corynebacterium microorganism having enhanced activity of a Mn transporter; a medium cultured therein; or a combination thereof.
[0147] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing purine nucleotides, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers, or isotonic agents.
[0148]
[0149] Another aspect of the present application provides a method for producing a microorganism of the genus Corynebacterium that produces purine nucleotides, comprising a step of enhancing the activity of a Mn transporter.
[0150] The above manufacturing method may include a step of modifying the microorganism so that the microorganism has increased Mn transporter activity compared to its intrinsic activity.
[0151]
[0152] Another aspect of the present application provides a use of a microorganism of the genus Corynebacterium having enhanced activity of a Mn transporter for producing purine nucleotides.
[0153]
[0154] The above Mn transporter, reinforcement, Corynebacterium genus microorganisms, etc. are as described in the other aspects above.
[0155]
[0156] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.
[0157]
[0158] Example 1: Production of vectors
[0159] Example 1-1: Production of a vector for increasing the copy number of the znuA1 gene
[0160] A vector was constructed to increase the copy number of the znuA1 (Ncam2275) gene (CP016326.1, SEQ ID NO: 2) encoding the Mn transporter (Iron / manganese / zinc ABC (TroA-like ATP-binding cassette) transporter) (WP_066796334.1, SEQ ID NO: 1).
[0161] Specifically, the chromosomal genes of the Corynebacterium stationensis wild-type ATCC6872 strain were isolated according to the protocol using the G-spin Total DNA extraction mini kit (Cat. No. 17045) from Intron, and PCR was performed using the primer pairs of SEQ ID NOs: 3 and 4, the primer pairs of SEQ ID NOs: 5 and 6, and the primer pairs of SEQ ID NOs: 7 and 8, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes. As a result, gene fragments of Pn / Ncam2275-A (1050 bp), Pn / Ncam2275-B (1648 bp), and Pn / Ncam2275-C (1048 bp) were obtained, respectively.
[0162] Using the three gene fragments obtained above as templates, a second PCR was performed under the same conditions to obtain a 3.6 kbp gene fragment. The obtained gene fragment was digested with the restriction enzyme XbaI (New England Biolabs, Beverly, MA) and cloned into the linear pDCM2 vector (Korean Patent Publication No. 10-2020-0136813) digested with the same restriction enzyme XbaI using T4 ligase (New England Biolabs, Beverly, MA). The prepared vector was named pDCM2-Pn / Ncam2275.
[0163] The primer sequences used in the above Example 1-1 are as shown in Table 1 below.
[0164]
[0165] SEQ ID NO Sequence Name Sequence (5'-> 3')3Pn / Ncam2275-A-FAATTCGAGCTCGGTACCCTGGCAAACTCAAATCCGGCT4Pn / Ncam2275-A-RTTTCTTAGCAGGTATGCGTAGGTCAAAGTATCGCC5Pn / Ncam2275-B-FTACTTTGACCTACGCATACCTGCTAAGAAATCC AC6Pn / Ncam2275-B-RGATTCGGTCTGCTTGAAGGATGGTTGGGCTTGCAT7Pn / Ncam2275-C-FAGCCCAACCATCCTTCAAGCAGACCGAATCCATCG8Pn / Ncam2275-C-RCGACTCTAGAGGATCCCCGTACCAAGCGTGAAGAGGTT
[0166] Example 1-2: Construction of a vector for increasing the copy number of the znuA1 gene and replacing the promoter.
[0167] A vector was constructed to increase the copy number of the znuA1 gene and replace the native promoter with the pCJ7 promoter (Republic of Korea Registration No. 10-0620092).
[0168] Specifically, PCR was performed using the chromosomal genes of the Corynebacterium stationensis wild-type ATCC6872 strain as a template and the primer pairs of SEQ ID NO: 9 and SEQ ID NO: 10, the primer pairs of SEQ ID NO: 11 and SEQ ID NO: 12, the primer pairs of SEQ ID NO: 13 and SEQ ID NO: 14, and the primer pairs of SEQ ID NO: 15 and SEQ ID NO: 16, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes. As a result, gene fragments of Pcj7 / Ncam2275-A (1050 bp), Pcj7 / Ncam2275-B (318 bp), Pcj7 / Ncam2275-C (1079 bp), and Pcj7 / Ncam2275-D (1048 bp) were obtained, respectively.
[0169] Using the four gene fragments obtained above as templates, a second PCR was performed under the same conditions to obtain a 3.5 kbp gene fragment. The obtained gene fragment was digested with the restriction enzyme XbaI and cloned into the linear pDCM2 vector digested with the same restriction enzyme XbaI using T4 ligase. The prepared vector was named pDCM2-Pcj7 / Ncam2275.
[0170] The primer sequences used in the above examples 1-2 are as shown in Table 2 below.
[0171]
[0172] SEQ ID NO Sequence Name Sequence (5'-> 3')9Pcj7 / Ncam2275-A-FAATTCGAGCTCGGTACCCTGGCAAACTCAAATCCGGCT10Pcj7 / Ncam2275-A-RcgctgggatgtttctGCGTAGGTCAAAGTATC GCC11Pcj7 / Ncam2275-B-FTACTTTGACCTACGCagaaacatcccagcgctact12Pcj7 / Ncam2275-B-RAGTCTGTAAATGCATgagtgtttcctttcgttgg g13Pcj7 / Ncam2275-C-FcgaaaggaaacactcATGCATTTACAGACTTCTCA14Pcj7 / Ncam2275-C-RGATTCGGTCTGCTTGAAGGATGGTTGGGCTTGCAT1 5Pcj7 / Ncam2275-D-FAGCCCAACCATCCTTCAAGCAGACCGAATCCATCG16Pcj7 / Ncam2275-D-RCGACTCTAGAGGATCCCCGTACCAAGCGTGAAGAGGTT
[0173] Example 1-3: Vector construction for introduction of Mn transporter
[0174] A vector was created to introduce the Mn transporter.
[0175] Specifically, PCR was performed using the chromosomal genes of the Corynebacterium stationensis wild-type ATCC6872 strain as a template, with primer pairs of SEQ ID NOs: 17 and 18, 19 and 20, and 21 and 22, respectively. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 7 minutes.
[0176] The gene fragment obtained above was fusion cloned into the linear pDCM2 vector digested with the restriction enzyme XbaI using the In-Fusion® HD cloning kit (Clontech). The prepared vector was named pDCM2-delNCam2155-NCam2275.
[0177] The primer sequences used in the above examples 1-3 are as shown in Table 3 below.
[0178]
[0179] SEQ ID NO Sequence Name Sequence (5'-> 3')17delNCam2155-NCam2275-A-FACGACGGCCAGTGAATTCGAGCTCGGTACCCGGGGATCCTgcgcggcaagaaggggggacc18delNCam2155-NCam227 5-A-RTCACTGAAAGCTTTCACGTCCATCGCACTAGTGGCGGCCGCagtttgcaccggctttgcca19delNCam2155-NCam2275-B-FACTAGTGCGATGGACGTGAA AGCT20delNCam2155-NCam2275-B-RGACCATGATTACGCCAAGCTTGCATGCCTGCAGGTCGACTgctaatgcgccctgggaatg21delNCam2155-NCam22 75-C-FAAAAGCCGGTGCAAACTGCCATACCTGCTAAGAAATCCACC22delNCam2155-NCam2275-C-RCGTCCATCGCACTAGTGCAAGGATGGTTGGGCTTGCATC
[0180] Example 2: Production of a Purine Nucleotide Producing Strain
[0181] Example 2-1: Production of a strain with increased copy number of the znuA1 gene
[0182] In order to construct a purine nucleotide producing strain, the pDCM2-Pn / Ncam2275 vector constructed in Example 1-1 was transformed into Corynebacterium stationanis KCCM12151P (CJI0323, Republic of Korea Registration No. 10-1904675), a 5'-inosine monophosphate (IMP) producing strain, by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), and then the strain in which the vector was co-integrated into the chromosome was first selected on a selection medium containing 25 mg / L of kanamycin. Thereafter, a second crossover process using the homology between the gene on the existing chromosome and the gene inserted through the vector was performed, thereby obtaining a strain in which the copy number of the endogenous znuA1 gene on the chromosome was increased to 2 copies. The strain was finally selected through genetic sequence analysis after performing PCR using the primer pair of SEQ ID NO: 23 and SEQ ID NO: 24. The strain in which the copy number of the znuA1 gene obtained through the above method increased to 2 copies was named KCCM12151P_Pn / Ncam2275.
[0183]
[0184] Example 2-2: Production of a strain with increased copy number of the znuA1 gene and a substituted promoter
[0185] In order to produce a purine nucleotide-producing strain with a stronger znuA1 gene than the strain of Example 2-1, the pDCM2-Pcj7 / Ncam2275 vector produced in Example 1-2 was transformed into Corynebacterium stationanis KCCM12151P, an IMP-producing strain, by electroporation, and then the strain with the vector inserted together on the chromosome was first selected on a selection medium containing 25 mg / L kanamycin. Thereafter, a second crossover process using the homology of the gene on the existing chromosome and the gene inserted through the vector was performed, thereby obtaining a strain in which the copy number of the endogenous znuA1 gene on the chromosome was increased to 2 copies and the promoter was replaced with the pCJ7 promoter. The strain was finally selected through gene sequence analysis after performing PCR using the primer pair of SEQ ID NO: 23 and SEQ ID NO: 24. The strain in which the copy number of the znuA1 gene obtained by the above method was increased to 2 copies and the promoter was replaced with the pCJ7 promoter was named KCCM12151P_Pcj7 / Ncam2275.
[0186] The primer sequences used in Examples 2-1 and 2-2 are as shown in Table 4 below.
[0187]
[0188] Sequence number Sequence name Sequence (5'-> 3') 23Pn / Ncsm2275-confirm_FGTCTCGTCCATCGATGGCAA 24Pn / Ncsm2275-confirm_RGCTGGCGACAACTGTGGTCT
[0189] Example 2-3: Production of a strain with a Mn transporter introduced
[0190] In order to construct a purine nucleotide producing strain, the pDCM2-delNCam2155-NCam2275 vector constructed in Example 1-3 was transformed into 5'-xanthosine monophosphate (XMP) producing strains Corynebacterium stationanis KCCM12285P (CJX1664, Republic of Korea Patent No. 10-1950141) and Corynebacterium stationanis KCCM12313P (CJX1682, Republic of Korea Patent No. 10-2006977) by electroporation, and then strains in which the vector was co-integrated into the chromosome were first selected on a selection medium containing 25 mg / L of kanamycin. Thereafter, a strain in which a Mn transporter was introduced into the chromosome was obtained through a second crossing process using the homology between the gene on the existing chromosome and the gene inserted through the vector. The strains were finally selected through genetic sequence analysis after performing PCR using primer pairs of SEQ ID NO: 17 and SEQ ID NO: 22. The strains into which the Mn transporter was introduced obtained through the above method were named CJX2591 (CJX1664_delNCam2155-NCam2275) and CJX2592 (CJX1682_delNCam2155-NCam2275), respectively.
[0191]
[0192] Example 3: Evaluation of IMP production ability of strains
[0193] In order to measure the IMP production ability of the KCCM12151P_Pn / Ncam2275 strain produced in the above Example 2-1, the KCCM12151P_Pcj7 / Ncam2275 strain produced in the above Example 2-2, and the control strain Corynebacterium stationenis KCCM12151P, a flask fermentation titer evaluation was performed.
[0194] The strain was inoculated into a 14 mL tube containing 2.5 mL of the following medium and cultured with shaking at 170 rpm at 30°C for 24 h. 2 mL of the culture medium was inoculated into a 250 mL corner-baffle flask containing 24 mL of the following fermentation medium (main medium) + 5 mL of a separate sterilized medium and cultured with shaking at 170 rpm at 30°C for 72 h. After completion of culture, the IMP concentration was measured using HPLC.
[0195] The composition of the above-mentioned seed medium and fermentation medium is as follows.
[0196]
[0197] <IMP 종배지>
[0198] Glucose 1%, peptone 1%, meat juice 1%, yeast extract 1%, sodium chloride 0.25%, adenine 100 mg / L, guanine 100 mg / L, pH 7.2
[0199]
[0200] <IMP 플라스크 발효배지 (본배지)>
[0201] Monosodium glutamate 0.1%, ammonium chloride 1%, magnesium sulfate 1.2%, calcium chloride 0.01%, iron sulfate 20 mg / L, manganese sulfate 20 mg / L, zinc sulfate 20 mg / L, copper sulfate 5 mg / L, L-cysteine 23 mg / L, beta-alanine 24 mg / L, nicotinic acid 8 mg / L, biotin 45 μg / L, thiamine hydrochloride 5 mg / L, adenine 30 mg / L, phosphoric acid (85%) 1.9%, glucose 4.2%, fructose 2.4%
[0202]
[0203] <IMP 플라스크 별도살균배지>
[0204] Phosphoric acid (85%) 23.3 g / L, ammonia (28%) 16.25 g / L, potassium hydroxide 25.5 g / L,
[0205]
[0206] The above experiment was repeated three times, and the average value of the analysis results is shown in Table 5 below.
[0207]
[0208] Strain name Residual sugar concentration (g / L) ODIMP concentration (g / L) KCCM12151P18.34 1.35.2 KCCM12151P_Pn / Ncam227516.14 3.65.5 KCCM12151P_Pcj7 / Ncam227513.94 5.55.8
[0209] As shown in Table 5 above, the KCCM12151P_Pn / Ncam2275 strain and the KCCM12151P_Pcj7 / Ncam2275 strain with enhanced znuA1 gene showed an improvement in sugar consumption rate with a 12% and 24% decrease in residual sugar amount, respectively, compared to the control strain in proportion to the degree of znuA1 gene enhancement, and an increase in IMP production by 5.7% and 11.5%, respectively.
[0210]
[0211] The above KCCM12151P_Pn / Ncam2275 strains and KCCM12151P_Pcj7 / Ncam2275 strains were named CJI-3141 and CJI-3142, respectively, and deposited with the Korea Microbiological Conservation Center, a depository institution under the Budapest Treaty, on September 8, 2022, and were assigned accession numbers KCCM13234P and KCCM13235P, respectively.
[0212]
[0213] Example 4: Evaluation of XMP production ability of strains
[0214] In order to measure the XMP production ability of the CJX2591 (CJX1664_delNCam2155-NCam2275) strain, CJX2592 (CJX1682_delNCam2155-NCam2275) strain produced in the above Example 2-3, and the control strains Corynebacterium stationenis KCCM12285P (CJX1664) and Corynebacterium stationenis KCCM12313P (CJX1682), a flask fermentation titer evaluation was performed.
[0215] The strain was inoculated into a test tube with a diameter of 18 mm containing 2 mL of the following medium and cultured with shaking at 170 rpm at 30°C for 24 hours. 0.7 mL of the culture medium was inoculated into a 250 mL corner-baffle flask containing 32 mL of the following fermentation medium (24 mL of main medium + 8 mL of a separate sterilized medium) and cultured with shaking at 170 rpm at 30°C for 75 hours. After completion of culture, the XMP concentration was measured using HPLC.
[0216] The composition of the above-mentioned seed medium and fermentation medium is as follows.
[0217]
[0218] <XMP 종배지>
[0219] Glucose 1%, Peptone 1%, Meat Juice 1%, Yeast Extract 1%, Sodium Chloride 0.25%, Adenine 100 mg / L, Guanine 100 mg / L, pH 7.5
[0220]
[0221] <XMP Flask Fermentation Medium (Main Medium)>
[0222] Glucose 40 g / L, Magnesium sulfate 10 g / L, Calcium chloride 100 mg / L, Iron sulfate 20 mg / L, Manganese sulfate 10 mg / L, Zinc sulfate 10 mg / L, Copper sulfate 0.8 mg / L, Histidine 20 mg / L, Cystine 15 mg / L, Beta-Alanine 15 mg / L, Biotin 100 ug / L, Thiamine 5 mg / L, Adenine 50 mg / L, Guanine 25 mg / L, Niacin 15 mg / L, pH 7.0
[0223]
[0224] <XMP flask separate sterilization medium>
[0225] Monopotassium phosphate 18 g / L, Monopotassium phosphate 42 g / L, Urea 7 g / L, Ammonium sulfate 5 g / L
[0226] The above experiment was repeated three times, and the average value of the analysis results is shown in Table 6 below.
[0227]
[0228] Strain name XMP concentration (g / L) XMP concentration increase rate (%) CJX16644.62-CJX25915.2212.98 % CJX168212.56-CJX259213.245.41 %
[0229] As shown in Table 6 above, the CJX2591 and CJX2592 strains were confirmed to have increased XMP production by 12.9% and 5.4%, respectively, compared to the control strains CJX1664 and CJX1682.
[0230]
[0231] Example 5: Evaluation of GMP production capacity of strains
[0232] In order to measure the 5'-guanosine monophosphate (GMP) production ability of the CJX2591 (CJX1664_delNCam2155-NCam2275) strain, CJX2592 (CJX1682_delNCam2155-NCam2275) strain produced in the above Example 2-3, and the control strains Corynebacterium stationenis KCCM12285P (CJX1664) and Corynebacterium stationenis KCCM12313P (CJX1682), a flask fermentation titer evaluation was performed using the same method as in Example 4. After completion of cultivation, the XMP concentration was measured using HPLC.
[0233] In order to convert the generated XMP into GMP, the following conversion reaction additives and XMP aminase of Escherichia coli were added to the above flask fermentation liquid, and the conversion reaction was performed at 40°C for 2.5 hours (Republic of Korea Patent No. 10-1210704). The conversion rate, which means the amount of GMP produced compared to the amount of XMP consumed after the reaction is shown in Table 7 below.
[0234]
[0235] Strain nameConcentration (g / L)Conversion rate (%)(GMP production / XMP consumption)XMPGMPCJX16644.603.3372.3CJX25915.213.8173.1CJX168212.498.9371.5CJX259213.189.5372.3
[0236] As shown in Table 7 above, the CJX2591 and CJX2592 strains showed an increase in XMP production by 14.4% and 6.7%, respectively, compared to the control strains CJX1664 and CJX1682, and the GMP conversion rate of the CJX2591 and CJX2592 strains was confirmed to be increased compared to the control strains CJX1664 and CJX1682.
[0237]
[0238] The above CJX2591 and CJX2592 strains were deposited with the Korea Microbiological Conservation Center, a depository institution under the Budapest Treaty, on September 8, 2022 and were assigned accession numbers KCCM13236P and KCCM13237P, respectively.
[0239]
[0240] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.
[0241]
[0242]
[0243]
[0244]
Claims
1. A microorganism of the genus Corynebacterium that produces purine nucleotides and has enhanced activity of the Mn transporter.
2. A microorganism according to claim 1, wherein the purine nucleotide is at least one selected from the group consisting of IMP, XMP, and GMP.
3. A microorganism according to claim 1, wherein the Mn transporter has an amino acid sequence of sequence number 1 or an amino acid sequence having at least 70% homology thereto.
4. In the first paragraph, the microorganism of the genus Corynebacterium has increased expression of the Mn transporter and enhanced activity of the Mn transporter compared to a wild-type Corynebacterium microorganism.
5. A microorganism according to claim 1, wherein the microorganism of the genus Corynebacterium is Corynebacterium stationis.
6. A method for producing purine nucleotides, comprising the step of culturing a Corynebacterium microorganism having enhanced activity of a Mn transporter and producing purine nucleotides in a medium.
7. A method according to claim 6, wherein the purine nucleotide is at least one selected from the group consisting of IMP, XMP, and GMP.
8. A composition for producing purine nucleotides, comprising a Corynebacterium microorganism having enhanced activity of a Mn transporter; a medium culturing the same; or a combination thereof.
